AXNX240517P60000
- 0.20
- 0.000.00%
Axonics Newsroom
Axonics Gets Australian Approval for Neurostimulator System
By Ben Glickman Axonics on Thursday said it had received approval from Australian regulators to market its recharge-free neurostimulator device. The Irvine, Calif.-based medical technology company s
Axonics Implant Approved in Australia to Treat Overactive Bladders
Axonics (AXNX) late Thursday said Australian regulators have cleared the company's Axonics F15 sacral neuromodulation device to treat adults with overactive bladders. The implant is relatively small a
Express News | Axonics Receives Approval From The Therapeutic Goods Administration For Marketing Of Axonics F15 In Australia
Express News | Axonics Receives Regulatory Approval for Recharge-Free Snm System in Australia
Express News | Needham Reiterates Hold on Axonics
Axonics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 — Needham Reiterates → Hold 02/29/2024 5.62% RBC Capital → $71 Reiterates Sector Perform → Sec
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Axonics Modulation Technologies (AXNX) and Artivion (AORT)
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)
Axonics Q1 EPS $(0.38) Misses $(0.08) Estimate, Sales $91.41M Beat $89.59M Estimate
Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by 375 percent. This is a 100 percent decrease over losses of $(0.19) per sh
Earnings Flash (AXNX) AXONICS Reports Q1 Revenue $91.4M
04:03 PM EDT, 04/30/2024 (MT Newswires) -- Earnings Flash (AXNX) AXONICS Reports Q1 Revenue $91.4M
Express News | Axonics Q1 Revenue USD 91.409 Million Vs. Ibes Estimate USD 89.9 Million
Express News | Axonics Q1 Operating Expenses USD 88.432 Million
Express News | Axonics Q1 Basic EPS USD -0.38
Express News | Axonics Q1 Gross Profit USD 69.253 Million
Express News | Axonics Reports First Quarter 2024 Financial Results
Axonics 1Q Loss/Shr 38c >AXNX
Axonics 1Q Loss/Shr 38c >AXNX
Express News | Axonics Q1 Operating Income USD -19.179 Million
Express News | Boston Scientific Corp- Sees Q2 EPS on a Gaap Basis in a Range of $0.35 to $0.37 and Adjusted EPS, of $0.57 to $0.59
Express News | Boston Scientific Corp- Sees Net Sales Growth for FY 2024, to Be in Range of Approximately 11 to 13 Percent on a Reported Basis
Express News | Boston Scientific Corp- Sees FY Adjusted EPS, Excluding Certain Charges (Credits), of $2.29 to $2.34